(Q43158088)

15 November 2017

title

Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer (English)

1 reference

15 November 2017

0 references

1 reference

Ronald C Chen

1

1 reference

15 November 2017

Harvey J Mamon

2

1 reference

15 November 2017

Yu-Hui Chen

3

1 reference

15 November 2017

Rebecca S Gelman

4

1 reference

15 November 2017

W Warren Suh

5

1 reference

15 November 2017

James A Talcott

6

1 reference

15 November 2017

Jeffrey W Clark

7

1 reference

15 November 2017

Theodore S Hong

8

1 reference

15 November 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

15 November 2017

1 reference

15 November 2017

volume

116

1 reference

15 November 2017

issue

8

1 reference

15 November 2017

page(s)

1879-1886

1 reference

The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Is cancer treatment toxicity accurately reported?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel–Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Symptom indexes to assess outcomes of treatment for early prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Bringing Prostate Cancer Quality of Life Research Back to the Bedside: Translating Numbers Into a Format That Patients can Understand

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Determining the Relationship Between Toxicity and Quality of Life in an Ovarian Cancer Chemotherapy Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Patient-reported outcomes and the evolution of adverse event reporting in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Handling missing data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Quality of life during radiotherapy for rectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24963

7 January 2021

Identifiers

DOI

10.1002/CNCR.24963

1 reference

15 November 2017

1 reference